Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at StockNews.com

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

KPTI has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. Robert W. Baird dropped their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Piper Sandler lifted their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Price Performance

KPTI stock opened at $0.77 on Friday. The company has a 50 day moving average price of $0.83 and a 200 day moving average price of $0.89. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95. The stock has a market capitalization of $96.37 million, a PE ratio of -0.67 and a beta of 0.16.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the firm earned ($0.30) EPS. As a group, equities analysts expect that Karyopharm Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently bought and sold shares of the business. Ikarian Capital LLC grew its holdings in shares of Karyopharm Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after buying an additional 9,355 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $31,000. Geode Capital Management LLC grew its holdings in shares of Karyopharm Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after buying an additional 43,856 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares during the period. Finally, FMR LLC grew its holdings in shares of Karyopharm Therapeutics by 26.1% in the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after buying an additional 76,510 shares during the period. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).